216 related articles for article (PubMed ID: 30048651)
21. The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.
Carbonnelle-Puscian A; Copie-Bergman C; Baia M; Martin-Garcia N; Allory Y; Haioun C; Crémades A; Abd-Alsamad I; Farcet JP; Gaulard P; Castellano F; Molinier-Frenkel V
Leukemia; 2009 May; 23(5):952-60. PubMed ID: 19436310
[TBL] [Abstract][Full Text] [Related]
22. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression.
Fang S; Xu T; Xiong M; Zhou X; Wang Y; Haydu LE; Ross MI; Gershenwald JE; Prieto VG; Cormier JN; Wargo J; Sui D; Wei Q; Amos CI; Lee JE
J Invest Dermatol; 2019 Nov; 139(11):2352-2358.e3. PubMed ID: 31176707
[TBL] [Abstract][Full Text] [Related]
23. FoxP3 and IDO in Canine Melanocytic Tumors.
Porcellato I; Brachelente C; De Paolis L; Menchetti L; Silvestri S; Sforna M; Vichi G; Iussich S; Mechelli L
Vet Pathol; 2019 Mar; 56(2):189-199. PubMed ID: 30381008
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of IL4-induced gene 1 enzyme by B2 cells during melanoma progression impairs their antitumor properties.
Bekkat F; Seradj M; Lengagne R; Fiore F; Kato M; Lucas B; Castellano F; Molinier-Frenkel V; Richard Y; Prévost-Blondel A
Eur J Immunol; 2024 Apr; 54(4):e2350615. PubMed ID: 38400692
[TBL] [Abstract][Full Text] [Related]
25. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
Kuklinski LF; Yan S; Li Z; Fisher JL; Cheng C; Noelle RJ; Angeles CV; Turk MJ; Ernstoff MS
Cancer Immunol Immunother; 2018 Jul; 67(7):1113-1121. PubMed ID: 29737375
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
27. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
28. The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: implications for melanoma progression.
Pepe CA; Ricci R; Cortelazzi C; Mori G; Zambito F; Campanini N; Aimi F; Santoro S; Lombardi M; Santini M; de Panfilis G
Eur J Dermatol; 2011; 21(2):178-83. PubMed ID: 21382782
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8
Hirose S; Mashima T; Yuan X; Yamashita M; Kitano S; Torii S; Migita T; Seimiya H
Cancer Sci; 2024 Mar; 115(3):791-803. PubMed ID: 38258342
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells.
Scarlata CM; Celse C; Pignon P; Ayyoub M; Valmori D
Eur J Immunol; 2015 Feb; 45(2):474-9. PubMed ID: 25446972
[TBL] [Abstract][Full Text] [Related]
31. [Impact of СD8/FoxP3 T lymphocyte ratio in the peritumoral area of primary cutaneous melanoma on the prognosis of the disease].
Bozhchenko YA; Vishnevskaya YV; Pokataev IA; Kokosadze NV; Demidov LV
Arkh Patol; 2016; 78(4):27-31. PubMed ID: 27600779
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
Shimizu A; Kaira K; Kato M; Yasuda M; Takahashi A; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Asao T; Ishikawa O
Melanoma Res; 2015 Oct; 25(5):399-405. PubMed ID: 26237765
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
[TBL] [Abstract][Full Text] [Related]
34. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
[TBL] [Abstract][Full Text] [Related]
35. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
[TBL] [Abstract][Full Text] [Related]
36. Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
Wu X; Wang X; Zhao Y; Li K; Yu B; Zhang J
Int J Med Sci; 2021; 18(7):1657-1669. PubMed ID: 33746582
[TBL] [Abstract][Full Text] [Related]
37. IL4-induced gene 1 is secreted at the immune synapse and modulates TCR activation independently of its enzymatic activity.
Aubatin A; Sako N; Decrouy X; Donnadieu E; Molinier-Frenkel V; Castellano F
Eur J Immunol; 2018 Jan; 48(1):106-119. PubMed ID: 28891065
[TBL] [Abstract][Full Text] [Related]
38. FOXP3 in Melanoma with Regression: Between Tumoral Expression and Regulatory T Cell Upregulation.
Cioplea M; Nichita L; Georgescu D; Sticlaru L; Cioroianu A; Nedelcu R; Turcu G; Rauta A; Mogodici C; Zurac S; Popp C
J Immunol Res; 2020; 2020():5416843. PubMed ID: 33274240
[TBL] [Abstract][Full Text] [Related]
39. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH
Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003
[TBL] [Abstract][Full Text] [Related]
40. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients.
Wang X; Xiong H; Liang D; Chen Z; Li X; Zhang K
BMC Cancer; 2020 May; 20(1):378. PubMed ID: 32370744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
